Skip to main content
Smart Investors Daily
Moderna, Inc. logo

NASDAQ · MRNA

Moderna, Inc.

Healthcare · Biotechnology

$199.33

Up+$2.54 (+1.29%)

Updated Nov 20, 2026, 11:59 AM

SID Score

6.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap
11.57B
P/E ratio
-3.71
Dividend yield
0.00%
52-week range
$36.66 – $280.80
Volume
8.2M
Avg. volume
11.3M

Price performance · MRNA

MRNA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

MRNA closed at $199.33 after 21 trading sessions, down 1.63% for the selected period.

Last close
$199.33
Period change
-1.63%
Period low
$196.79
Period high
$269.00
Daily close
View OHLC price history
MRNA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$196.03$205.2199$189.98$199.338.2M
Nov 18, 2026$206.80$208.68$196.52$196.796.99M
Nov 17, 2026$219.85$222.425$203.835$206.808.28M
Nov 16, 2026$216.74$220.5914$212.50$215.277.02M
Nov 13, 2026$224.90$231.35$221.70$223.378.09M
Nov 12, 2026$237.88$245.37$229.69$231.357.02M
Nov 11, 2026$252.78$254.86$243.00$248.697.59M
Nov 10, 2026$265.885$272.9999$250.49$250.8311.15M
Nov 9, 2026$257.855$280.80$253.33$269.0012.36M
Nov 6, 2026$245.40$267.50$237.8587$254.1916.33M
Nov 5, 2026$258.01$261.00$237.65$241.4612.03M
Nov 4, 2026$234.995$258.72$230.21$258.3814.81M
Nov 3, 2026$222.015$235.50$220.23$228.449.52M
Nov 2, 2026$224.16$230.5199$217.62$220.838.44M
Oct 30, 2026$220.53$227.81$217.22$221.729.01M
Oct 29, 2026$216.43$225.00$215.35$222.7610.83M
Oct 28, 2026$204.00$218.16$202.62$214.16512.04M
Oct 27, 2026$192.23$208.87$179.53$207.9717.64M
Oct 26, 2026$186.904$203.82$181.65$198.8517.11M
Oct 23, 2026$196.69$206.97$183.00$200.1021.57M
Oct 22, 2026$240.125$241.2642$180.80$202.6349.95M

Latest MRNA news

The latest Smart Investors Daily articles mentioning MRNA.

MRNA research

Overview

Company profile and research snapshot.

Company profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$29.64
Implied upside
—
Analysts
29
MRNA recent ratings
DateFirmRatingTarget
Nov 17, 2026JP MorganUnderweight—
Nov 17, 2026Morgan StanleyEqual-Weight—
Nov 9, 2026Piper SandlerOverweight—
Nov 9, 2026Goldman SachsNeutral—
Oct 27, 2026William BlairMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.